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THE FDA AND NANO: BIG PROBLEMS WITH TINY TECHNOLOGY
JESSICA K. FENDER*
INTRODUCTION
Nanotechnology is, simply put, tiny technology. The term refers to
technology that either is created on, or capable of manipulating, the nano-
scale.1 Although this field holds great promise, caution must be exercised
to ensure the safety and efficacy of products utilizing nanotechnology.
We are in the midst of a nanotechnology revolution. Our understand-
ing of the world changed drastically with the advent of quantum mechan-
ics, when scientists discovered that contrary to the rules of classical
physics, matter took on novel and unexpected properties when observed at
the nanoscale. Electrons, thought to be discrete particles, could act like
waves. Scientists could not pin down both the exact momentum and the
position of a particle; one property could not be measured with certainty
when the other was accurately measured. Exploring the implications of
these strange phenomena led to heady discoveries, and our view of the
universe around us changed forever.
It was not until relatively recently, however, that scientists and engi-
neers were able to steer their research in such a way as to take advantage of
* Editor-in-Chief, Chicago-Kent Law Review, 2007-2008; J.D. Candidate, Chicago-Kent Col-
lege of Law, 2008. 1 would like to thank Professors Lori Andrews and Julie Burger for their patience
and thoughtful criticism. I would also like to thank Steve and Lynn Fender, Adam Augustyn, and Dana
Lobelle for their unflagging support. Some of the background research for this article was completed at
the Institute for Science, Law and Technology and was funded by a grant from the Office of Science
(BER), U.S. Department of Energy, Grant No. DE-FG02-06ER64276. The views and opinions ex-
pressed herein are solely the author's own and do not reflect those of the United States Government or
any agency thereof.
1. Nanotechnology is not a single "technology," because the phrase applies to a wide variety of
technologies that could potentially involve manipulation of, or creation on, the nanoscale. The prefix
"nano" means "one-billionth"-a nanometer is therefore one billionth of a meter and is denoted "nm."
To put this in perspective, a sheet of paper as viewed from the side has a thickness of approximately
80,000-100,000 nanometers. Although the FDA and many other regulatory agencies have not officially
adopted a definition of nanotechnology, most informally use the National Nanotechnology Initiative
(NNI) definition: Nanotechnology involves (1) the research and technology development at the atomic,
molecular, or macromolecular levels, on a scale of about 1-100 nm; (2) the creation and use of struc-
tures, devices, and systems that have novel properties and functions due to their size; and (3) the ability
to control or manipulate on the atomic scale. U.S. Food & Drug Admin., FDA Nanotechnology-
FAQ's, http://www.fda.gov/nanotechnology/faqs.html (last visited Apr. 6, 2008) [hereinafter FDA
Nanotechnology FAQ].
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these queer properties. In 1959, the preeminent physicist Richard Feynman
hypothesized that manipulation of individual atoms might be possible. He
challenged the scientific community, asking his colleagues "to consider the
final question .... What would happen if we could arrange the atoms one
by one the way we want them[?]
' '2
The world is starting to find out. Though Feynman's enthusiasm ulti-
mately proved contagious, it was not until the 1980s that the idea became a
reality with the invention of the scanning tunneling microscope, or STM.
3
The STM is widely described as the first nanotechnology-related invention
because the microscope could take advantage of the wave-like properties of
electrons to indirectly image and manipulate individual atoms. 4 Since then,
the field has grown by leaps and bounds. Researchers now have a wealth of
nanomaterials at their disposal. These include, for example, quantum dots,
which are semiconducting nanocrystals; fullerenes, which are spherical
carbon cages; and nanowires, which generally are one-dimensional strings
of a metallic or semiconducting compound. 5 These materials can be used in
diverse fields such as semiconductor design, biotechnology, materials sci-
ence, telecommunications, and textiles, because nanotechnology is applica-
ble in just about any field where small size, large surface area, or quantum
properties are desirable. 6
The wide-ranging applicability of nanotechnology-related research has
captured the attention of the U.S. government. Federal funding will reach
more than $1.5 billion in 2009, 7 which is a 50% increase over the amount
available in 2005.8 In December of 2003, President George W. Bush signed
2. Richard P. Feynman, There's Plenty of Room at the Bottom, in MINIATURIZATION (Horace D.
Gilbert ed., 1961), reprinted in 60 J. OF MICROELECTROMECHANICAL SYS. 60, 65 (1992).
3. Davis Baird & Ashley Shew, Probing the History of Scanning Tunneling Microscopy, in
DISCOVERING THE NANOSCALE 145, 145-46 (Davis Baird, Alfred Nordmann & Joachim Schummer
eds., 2004).
4. Id. at 146.
5. 1 say "generally" because nanotechnology terminology is not uniform, and often overlaps.
Some terms are too broad to provide any tangible insight into the structure of the molecule. For exam-
ple, when one searches for the word "nanoparticle" within the "claims" section of a U.S. patent, one
will find references to nanoparticles from 1-100,000 nanometers, well into the micrometer range.
People also occasionally use the same term to refer to two different materials. For example, one person
might refer to a given material as a nanowire, whereas another might call the same material a nanotube.
A nanowire is usually defined as above, while a nanotube is generally recognized as having the same
carbon connectivity as a fullerene in hollow tube form instead of spherical form. To view images of
nanotubes and fullerenes, see PAUL HOLISTER, TIM HARPER & CRISTINA ROMAN VAS, CMP-
CIENTiFICA, NANOTUBES 7-8 (2003), available at http://nanotechweb.org/dl/wp/nanotubes.WP.pdf.
6. Mark A. Lemley, Patenting Nanotechnology, 58 STAN. L. REV. 601, 614 (2005).
7. Nat'l Nanotechnology Initiative, Funding, http://wwv.nano.gov/html/about/funding.html (last
visited Apr. 4, 2008) [hereinafter NNI Funding).
8. David J. Robeson, Nanotechnology and the USPTO, THE DISCLOSURE, May 2006,
http://www.napp.org/disclosure/2006_Issues/may06.html.
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the 21 st Century Nanotechnology R&D Act into law, providing $3.7 billion
for nanotechnology research for 2005-2008. 9 Since 2001, the administra-
tion has increased nanotechnology funding by 83%. l0 Most of this funding
goes to the National Nanotechnology Initiative (NNI).l' The NNI then
portions this funding out to other governmental funding agencies. In 2008,
NNI estimates that the Department of Defense will receive the most fund-
ing at $487 million, followed by the National Science Foundation at $389
million. 12 Other governmental agencies receiving significant funding in-
clude the Department of Energy ($251 million); the Department of Health
and Human Services, which includes the National Institute of Health ($226
million); the Department of Commerce, which includes the National Insti-
tute of Standards and Technology ($89 million); and the National Aeronau-
tics and Space Administration ($18 million).13
Venture capitalists are also funding nanotechnology research. Since
1995, they have invested at least $2 billion worldwide; 14 some estimate that
they invested $650 million in 2006 alone. 15 This amount, while significant,
is dwarfed by the $1.9 billion that North American corporations invested in
nanotechnology research and development in 2005.16 Clearly, funding from
the corporate sector, venture capitalists, and the government illustrates
substantial support for nanotechnology.
The availability of funding and the potential financial rewards com-
bine to create a significant incentive to undertake nanotechnology research
and development. In the rush to capitalize, the government has not given
adequate consideration to the risks that nanotechnology-related products
and inventions may pose to public health and safety. Nanotechnology is
special in that it is applicable across many fields, but it is this very trait that
makes nanotechnology so difficult to regulate. Although the government is
largely funding research efforts in the United States, it has not done enough
9. 15 U.S.C. § 7505 (Supp. IV 2004); Press Release, Office of the Press Secretary, President
Bush Signs Nanotechnology Research and Development Act (Dec. 3, 2003), available at
http://www.whitehouse.gov/news/releases/2003/12/20031203-7.html.
10. See Press Release, supra note 9.
II. NN1 Funding, supra note 7.
12. Id.
13. Id.
14. Press Release, Lux Research, Inc., Venture Capital Pours into Nanotech, but Exits Are Uncer-
tain (Jan. 9, 2006), available at http://www.luxresearchinc.com/press/RELEASEVC.pdf
15. Press Release, Lux Research, Inc., Nanotech Venture Capital To Exceed $650 Million in 2006
(Dec. 4, 2006), available at http://www.luxresearchinc.com/press/RELEASE-VCreport.pdf.
16. Lux RESEARCH, INC., THE NANOTECH REPORT 4TH EDITION: KEY FINDINGS AND TABLE OF
CONTENTS, at iii (2006), available at http://www.luxresearchinc.com/pdf/TNR4_TOC.pdf, see Kevin
Kelleher, Nanotech Is Living Large, THE STREET, Apr. 13, 2006, http://www.thestreet.com/tech/inter




to ensure that these efforts will ultimately benefit, and not harm, its citi-
zens. As one critic stated, the government "has acted as a cheerleader, not a
regulator, in addressing the nanotech revolution."'17 In fact, of all the
money the federal government has invested in nanotechnology, only about
5% is expressly allocated for environmental, health, and safety research in
2009.18
The government's responsibility to invest in environmental, health,
and safety research does not arise solely based on its funding of nanotech-
nology research and development. Nanotechnology squarely implicates
many federal regulatory bodies. For example, nanotechnology inventions
are patented in the United States Patent and Trademark Office (USPTO),
certain nanotechnology products must be approved by the Food and Drug
Administration (FDA) before they can be used or offered for sale, the Na-
tional Institute for Occupational Safety and Health (NIOSH) is supposed to
ensure that workers are not exposed to hazardous nanomaterials, and the
Environmental Protection Agency (EPA) must monitor nanotechnology
products to guarantee that they do not pose an environmental threat. Some
of these agencies have already adopted a nanotechnology policy; others are
still struggling to define their official stance.
Such is the case with the FDA. Thus far, the FDA has insisted that its
present regulatory scheme is adequate to the task of analyzing nanotech-
nology products.19 This ad hoc approach has been strongly criticized, 20 and
for good reason. Some have cushioned their criticism of the FDA by point-
ing out that "nano-enabled drugs and medical devices ... place burdens on
an oversight agency that is already stretched extremely thin.' '21 Although
17. Kathy Jo Wetter, ETC Group, Remarks at the Public Meeting on Nanotechnology Materials in
FDA Regulated Products 119 (Oct. 10, 2006), transcript available at http://www.fda.gov/nanotech
nology/meetings/transcript.pdf.
18. The 2009 proposed budget for the National Nanotechnology Initiative is $1,527 million; of
that, NNI estimates that $76 million (or 4.9%) will be spent on environmental, health, and safety re-
search. NNI Funding, supra note 7; Nat'l Nanotechnology Initiative, NNI Environmental, Health &
Safety Issues, http://www.nano.gov/html/society/EHS.html (last visited Apr. 4, 2008) [hereinafter NNI,
EHS Issues]. This number may be low, since the NNI website states that the figure "does not include
substantial research in instrumentation and metrology and on fundamental interactions between biosys-
tems and engineered nanoscale materials, both of which are important in the performance and interpre-
tation of toxicological research." NNI, EHS Issues, supra.
19. FDA Nanotechnology FAQ, supra note 1 (stating that "[e]xisting requirements may be ade-
quate for most nanotechnology products that [the FDA] will regulate"); Carol Rados, Nanotechnology:
The Size of Things to Come, FDA CONSUMER, Nov.-Dec. 2005, at 40, 42 ("For the most part, FDA
experts believe that existing regulatory standards are probably adequate for most nanotechnology
products. Scientists say that particle size is not the issue. Instead, new tests and standards will be re-
quired as new toxicological risks from the new materials are identified.").
20. E.g., FDA Told to Watch Nanotech Products for Risks, MSNBC.cOM, Oct. 10, 2006,
http://www.msnbc.msn.com/id/15213085/.
21. Id. (quoting David Rejeski, director of the Project on Emerging Nanotechnologies).
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the FDA undoubtedly does not have the funding it needs, 22 nothing pre-
vents the FDA from taking advantage of valuable information that is freely
disclosed by other agencies. The USPTO, for example, recently created a
new cross-reference classification number for nanotechnology-related pat-
ents. This cross-reference class, Class 977, is evidence that the USPTO
thinks an invention relates to nanotechnology and has novel properties that
are not the natural result of the invention's small scale. As it stands, if the
invention falls under the FDA's jurisdiction, the FDA will treat that inven-
tion exactly the same as its large-scale counterpart--despite the USPTO's
indication that the invention has unique, nanotechnology-related properties.
In this note, I argue that the FDA should use the Class 977 label to identify
products that warrant stricter regulatory controls. This label is a simple,
inexpensive way to identify products that are likely to require special scru-
tiny before being released on the market. In addition, due to the manner in
which the USPTO defined Class 977, the label applies most often to (and is
therefore of greatest use for) those products that would otherwise receive
the weakest regulatory oversight from the FDA.
Part I of this note challenges the FDA's premise that nanotechnology-
related products pose no special threat by providing evidence that a nano-
material may have very different physical and toxicological properties than
the same material on the macroscale. Part II provides a counterbalance by
identifying the unique benefits that may follow from these special proper-
ties, and shows how the same property that is harmful in one context can
actually prove beneficial in another. Part III details the FDA's current ap-
proach to nanotechnology and explains why this approach will not suffice
to ensure the public health and safety. In Part IV, the USPTO's approach to
nanotechnology is discussed, along with the evolution of Class 977. Part V
argues for the applicability of Class 977 to the FDA's regulatory scheme,
and further argues that the FDA should use its labeling powers and its Of-
fice of Combination Products to ensure the safety of Class 977-labeled
products. Finally, Part VI of this note urges the FDA to take decisive action
in addressing nanotechnology product safety. Nanotechnology has the po-
tential to transform our lives, but this potential will be wasted if the FDA
does not take an aggressive stance in assuring the public that nanotechnol-
ogy products are safe.
22. MICHAEL R. TAYLOR, REGULATING THE PRODUCTS OF NANOTECHNOLOGY: DOES THE FDA




I. BIG PROBLEMS WITH TINY TECHNOLOGY
Nanotechnology is technology created on a very small scale. An atom
or molecule created on the nanoscale may have very different physical
properties than the same atom or molecule in its naturally occurring state.
For instance, most people are familiar with gold-it is yellow, it melts at
about 1000°C, and it is (thankfully) non-reactive. 23 On the nanoscale,
things look quite different. As one researcher noted, "not one of these
'facts' necessarily applies at the nanoscale. ' '24 For instance, at 5 nm, gold is
expected to melt at 8301C, and at 2 nm, it would melt at just 3501C.25 Even
the magnetic properties of a material can change-aluminum is not usually
magnetic, but it becomes magnetic when individual atoms form a cluster
with a diameter of less than 1 nm, 26 and at 20-30 nm, aluminum will ex-
plode.27 Similarly, at the nanoscale an insulating material may change into
a conductor, and a previously insoluble material may become soluble.28
Most importantly, however, the size of a particle does not allow one to
predict which, if any, changes in the particle's "normal behavior" will oc-
cur. As a National Geographic author described, "It's like you shrink a cat
and keep shrinking it, and then at some point, all at once, it turns into a
dog."'29 Physical properties change, and those changes are not limited to
properties inherent to small size.
Many reputable sources are expressing concerns regarding nanotech-
nology safety due to the potential these materials have to exhibit novel,
unpredictable properties. 30 Although the FDA says that it is "not aware of
any adverse safety issues associated with the use of nanotechnology-based
materials in FDA regulated products,"131 a plethora of scientific evidence
23. Michael Cortie, The Weird World of Nanoscale Gold, 37 GOLD BULL. 12, 14-16 (2004) (cita-
tions omitted).
24. Id. at 14.
25. Id. at 16.
26. W. Eberhardt, Clusters as New Materials, 500 SURFACE SCI. 242, 244 (2002).
27. Jennifer Kahn, Nano's Big Future, NAT'L GEOGRAPHIC, June 2006, at 98, 100.
28. Delara Karkan, Associate Director, Center for Evaluation of Radiopharmaceuticals, Health
Canada, Remarks at the Public Meeting on Nanotechnology Materials in FDA Regulated Products 39
(Oct. 10, 2006), transcript available at http://www.fda.gov/nanotechnology/meetings/transcript.pdf.
29. Kahn, supra note 27, at 103.
30. The American Chemical Society's Committee on Chemical Safety, for example, is advising
chemists to take precautions when working with nanoparticles because "[s]tudies have indicated that
low-solubility ultrafine particles are more toxic than larger particles on a mass for mass basis. Because
of their tiny size, [nanoparticles] can get deep into the lungs and, once in the bloodstream, may be able
to cross the blood-brain barrier." Am. Chem. Soc'y, Nanotechnology Safety Resources,
http://membcrship.acs.org/c/ccs/nano.htm (last visited Apr. 4, 2008).
3 1. Randy Lutter, Co-Chair of the FDA Task Force on Nanotechnology, Opening Remarks at the
Public Meeting on Nanotechnology Materials in FDA Regulated Products 5 (Oct. 10, 2006), transcript
available at http://www.fda.gov/nanotechnology/meetings/transcript.pdf.
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points to the potential dangers of nanotechnology products. Sophisticated
computer models provide strong evidence that buckminsterfullerenes (a
specific type of fullerene also referred to as C60) will bind and deform dou-
ble-stranded DNA and prevent the DNA repair mechanism from working
correctly. 32 When this happens, it can lead to genetic mutations that cause
cancer and other diseases. 33 In largemouth bass, buckminsterfullerenes
cause an increase in lipid peroxidation, thereby causing cellular damage in
the brain.34 Another scientific paper reports that when nanoparticles are
taken up into cells, they become coated with proteins. 35 This process results
in conformational changes, causing normally buried portions of the protein
to become exposed. Instead of rejecting the molecule as a foreign body, the
cell may instead trigger "inappropriate cellular processes '' 36 which may
prevent a body's normal immune system from clearing the nanoparticle. 37
Carbon nanotubes pose a special threat to the lungs. Mice that inhale sin-
gle-walled nanotubes experience respiratory deficiencies and cannot clear
bacteria from their lungs as efficiently as mice that are not exposed to
nanotubes. 38 Furthermore, using extremely fine carbon black particles or
fine crystalline silica does not have the same effect, indicating that "the
biological and toxicological effects of [carbon nanotubes] cannot be pre-
dicted by extrapolation of data collected with fine carbon particles.
'39
These results provide evidence that there is something exceptional (and not
simply size dependent) about the carbon nanotubes themselves.
These are just a few examples of studies that have called attention to
the potential risks of nanomaterials. To dismiss these results out of hand
32. Xiongce Zhao, Alberto Striolo & Peter T. Cummings, C60 Binds to and Deforms Nucleotides,
89 BIOPHYS. J. 3856, 3856 (2005).
33. See, e.g., Viola Ellison & Bruce Stillman, Biochemical Characterization of DNA Damage
Checkpoint Complexes: Clamp Loader and Clamp Complexes with Specificity for 5' Recessed DNA, I
PLoS BIOLOGY 231, 231 (2003); NIH DNA Repair Interest Group, What is DNA Repair?
http://www.nih.gov/sigs/dna-rep/whatis.html (last visited Apr. 4, 2008).
34. Eva Oberd5rster, Manufactured Nanomaterials (Fullerenes, C6o) Induce Oxidative Stress in
the Brain of Juvenile Largemouth Bass, 112 ENVTL. HEALTH PERSP. 1058, 1060 (2004). Lipid peroxi-
dation is the process whereby free radicals (atoms or molecules that have an unpaired electron and
therefore are highly reactive) "steal" electrons from lipids in the cell membrane, causing cell damage
and increased production of free radicals.
35. Iseult Lynch, Kenneth A. Dawson & Sara Linse, Detecting Cryptic Epitopes Created by
Nanoparticles, SCI. STKE, Mar. 21, 2006, at pel4-1.
36. Id. at pe14-3.
37. T. Fettah Kosar, Anna Tourovskaia & Nicholas L. Stucky, Nanoparticles Administered to the
Human Body: Impacts and Implications, NEWS FROM THE BOTTOM, 2004 (on file with the Chicago-
Kent Law Review).
38. Anna A. Shvedova et al., Unusual Inflammatory and Fibrogenic Pulmonary Responses to
Single-Walled Carbon Nanotubes in Mice, 289 AM. J. PHYSIOL.-LUNG CELL. MOL. PHYSIOL. L698,
L698 (2005).
39. Id. at L706.
2008]
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would be to willfully ignore a potential threat to the public. But although
these concerns must be taken seriously, the federal government also has an
obligation not to overreact to perceived threats. Some have suggested ban-
ning further nanotechnology research and recalling nanotechnology prod-
ucts until the safety of such products is conclusively determined.40 Such a
ban would likely not only be impossible, but irresponsible. There is little
doubt that nanotechnologies will drastically improve our quality of life, and
banning nanotechnology research entirely would both prevent life-saving
products from reaching the market and decimate public confidence in the
safe and effective nanotechnology products that will reach (and may al-
ready be on) the market.
II. THE BIG PROMISE OF TINY TECHNOLOGY
Researchers and theorists have long painted some truly incredible vi-
sions of our future. Nanotechnology will help those visions come to life.
For example, NASA is actively considering the use of carbon nanotubes to
build an elevator from Earth to space.41 Perhaps more importantly,
nanotechnology is already having a beneficial impact on public health.
42
Quantum dots are being used to detect precancerous biomarkers, and have
proven successful in the early detection of cervical and breast cancer.
43
Other nanoparticles may specifically target and destroy cancer cells, leav-
ing healthy cells untouched. 44 Researchers at MIT are using a self-
assembling nanoliquid made of peptides to stop bleeding in less than fifteen
seconds, which could significantly reduce the time spent in surgery. 45 The
nanoliquid is applied directly to a wound, and because the liquid is made of
40. E.g., Erich Pica, Friends of the Earth, Remarks at the Public Meeting on Nanotechnology
Materials in FDA Regulated Products 151 (Oct. 10, 2006), transcript available at
http://www.fda.gov/nanotechnology/meetings/transcript.pdf; Press Release, ETC Group, Nanotech
Product Recall Underscores Need for Nanotech Moratorium: Is the Magic Gone? (Apr. 7, 2006), avail-
able at http://www.etcgroup.org/upload/publication/14/01/nrnanorecallfinal.pdf.
41. Kenneth Chang, Not Science Fiction: An Elevator to Space, N.Y. TIMES, Sept. 23, 2003, at Fl,
F4.
42. Note, however, that many of applications discussed below remain relegated to the laboratory
and may not have been approved for use on humans. In addition, some applications, such as the use of
quantum dots for tissue imaging, will not require human testing since the tissues are removed and
treated prior to being examined under a microscope or similar imaging apparatus.
43. Dawn L. Nida et al., Fluorescent Nanocrystals for Use in Early Cervical Cancer Detection, 99
GYNECOLOGIC ONCOLOGY S89 (2005); Jennifer Ouellette, Quantum Dots for Sale, INDUS. PHYSICIST,
Feb.-Mar. 2003, at 14, 15.
44. Ray Kurzweil, Reprogramming Biology, SCI. AM., July 26, 2006, at 38.
45. Rutledge Ellis-Behnke et al., Nano Hemostat Solution: immediate Hemostasis at the Nano-
scale, 2 NANOMEDICINE: NANOTECH., BIOL., & MED. 207 (2006); Anne Trafton, New Material Halts
Bleeding, TECH TALK (Mass. Inst. of Tech., Cambridge, Mass.), Oct. 2006, at 1, available at
http://web.mit.edu/newsoffice/2006/techtalk51-5.pdf.
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peptides (which are the building blocks of naturally occurring proteins) the
material does not provoke a negative immune response in test animals. 46
There is even evidence that nanotechnology might ultimately provide a
cure for type I diabetes, as one scientist has cured the disease in rats using a
nanodevice that releases insulin while blocking antibodies.47 Other impor-
tant nanotechnology applications include treatment of nausea, organ rejec-
tion, cholesterol, and loss of appetite due to anorexia or AIDS.48
Many features of nanotechnology can be harmful under one set of cir-
cumstances and beneficial under another. For instance, one oft-cited con-
cern about nanomaterials is that they may cross the blood-brain barrier. 49
Nanoparticles used to keep windows clean or food fresh could pose a seri-
ous hazard to the consumer if the particles could get into that consumer's
brain tissue. On the other hand, a promising drug that seems to work well
but lacks efficiency might be "nanosized" to cross the blood-brain barrier,
leading to greater functionality for the drug.50 Nanosizing a drug can also
lead to increased efficiency simply by increasing the surface area of the
drug.51 If drugs can be nanosized to have increased efficacy against viral
infections, such a change would benefit both the individual patient (who
may take less of the drug or recover more rapidly) and the public at large,
because efficient drugs eliminate viruses before they have time to mutate or
adapt into new, drug-resistant strains. 52
Similarly, buckminsterfullerenes apparently localize in certain tissues
(like the brain) to cause harmful side effects, 53 much as carbon nanotubes
localize and cause harm to the lungs. 54 But a different nanomaterial may be
targeted to a specific area of the body to great benefit. For example, at Rice
University researchers are treating cancer using "nanoshells" of gold-
46. Ellis-Behnke et al., supra note 45, at 214.
47. Kurzweil, supra note 44.
48. All of these drugs have received FDA approval and are commercially available. See Project on
Emerging Nanotechnologies, Current Medical Applications, http://www.nanotechproject.org/inven
tories/medicine/apps/ (last visited Apr. 4, 2008).
49. The blood-brain barrier is "a naturally occurring barrier created by the modification of brain
capillaries... that prevents many substances from leaving the blood and crossing the capillary walls
into the brain tissues." MERRIAM-WEBSTER'S COLLEGIATE DICTIONARY 133 (1 th ed. 2003).
50. Kosar, Tourovskaia & Stucky, supra note 37.
51. Elan Drug Technologies, NanoCrystal Technology, http://www.elan.com/EDT/nanocrystal
technology/default.asp (last visited Apr. 4, 2008). See infra note 141 for an explanation as to why
surface area may affect drug efficacy.
52. Anil Diwan, NanoViricides, Inc., Remarks at the Public Meeting on Nanotechnology Materi-
als in FDA Regulated Products 191-92 (Oct. 10, 2006), transcript available at
http://www.fda.gov/nanotechnology/meetings/transcript.pdf. Viral mutations have created enormous
problems in the treatment of illnesses and diseases like malaria and AIDS, as well as the common flu.
53. See supra notes 32-37 and accompanying text.
54. See supra notes note 38-39 and accompanying text.
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coated silica that absorb infrared light; combined with antibodies, the
nanoshells localize in tumors. 55 Once the particles are concentrated in the
tumor, the researchers hit the tissue with infrared light, destroying the tu-
mor while leaving non-cancerous tissue untouched. The same nanoshells
may have additional uses, such as in welding tissues together to treat a bum
victim. 56 These examples illustrate why a case-by-case evaluation of
nanotechnology product safety is needed. One simply cannot draw gener-
alizations about all nanomaterials from the characteristics of one; further,
even those characteristics that can be generalized across all nanomaterials
may prove useful in certain contexts and dangerous in others.
III. THE FDA'S CURRENT APPROACH
The FDA is an agency within the Department of Health and Human
Services, and it is comprised of various centers. 57 These include, for exam-
ple, the Center for Biologics Evaluation and Research (CBER), the Center
for Devices and Radiological Health (CDRH), the Center for Drug Evalua-
tion and Research (CDER), and the Center for Food Safety and Applied
Nutrition (CFSAN). 58 Each of these centers is further divided into several
offices. For example, CBER includes an office dedicated to cellular, tissue,
and gene therapies and an office for vaccine research and review, among
others. 59 Through these centers, the FDA regulates products accounting for
approximately twenty-five cents of every dollar spent by American con-
sumers. 60 Perhaps this is unsurprising, as the FDA regulates a diverse vari-
ety of products including foods and food additives, cosmetics, dietary
supplements, animal feeds, pharmaceuticals, medical devices, radiation-
emitting electronics, vaccines, blood products, tissues, and sterilants. 61
The FDA's mission, by its very nature, is to engage in a balancing test
whereby strict regulatory controls are pitted against the need to get useful
and often life-saving products on the market in a timely fashion. The
55. Christopher Loo et al., Nanoshell-Enabled Photonics-Based Imaging and Therapy of Cancer,
3 TECH. CANCER RES. & TREATMENT 33 (2004).
56. Andre M. Gobin et al., Near Infrared Laser-Tissue Welding Using Nanoshells as an Exoge-
nous Absorber, 37 LASERS 1N SURGERY & MED. 123 (2005).
57. U.S. Food & Drug Admin., FDA Organization Charts, http://www.fda.gov/oc/orgcharts/org
chart.html (last visited Apr. 6, 2008).
58. Id.
59. Id.
60. Henry I. Miller, The Wrong Choice for the FDA, WALL ST. J., June 26, 1998, at A14.
61. Nakissa Sadrieh, Associate Director for Research Policy and Implementation, U.S. Food &
Drug Admin., Address at the Nanobusiness Conference 2005: FDA Consideration for Regulation of
Nanomaterial Containing Products (May 24, 2005), slides available at http://www.fda.gov/NANO
TECHNOLOGY/powerpoint-conversions/mayO5.html.
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FDA's regulatory scheme is therefore designed for adaptability, and it is
built on the recognition that different products require different levels of
regulation to ensure the public safety. General adaptability, however, can
be stretched only so far before it breaks down, and despite the demonstra-
bly unique properties of nanotechnology-containing products, the FDA
states that "[e]xisting requirements may be adequate for most nanotechnol-
ogy products that [the FDA] will regulate." 62 The FDA expresses this view
because it believes that a new nanotechnology material would be the same
size "as the cells and molecules with which FDA reviewers and scientists
associate every day. In particular, every degradable medical device or in-
jectable pharmaceutical generates particulates that pass through this size
range during the processes of their absorption and elimination by the
body." 63
While this may be true, the FDA's conclusion that its current regula-
tory scheme is adequate does not logically follow. First, as illustrated
above, the size of a product does not dictate the product's behavior or
safety. Size does not necessarily give rise to a particular property; instead, a
certain size (on the order of nanometers) provides a strong indication that
novel properties may also exist. Second, the nanoscale products with which
the FDA claims familiarity are medical devices and pharmaceuticals-
products that are often designed to specifically pass through the nanoscale.
Some new drugs, for example, are constructed to fit into a protein's "active
site" and thereby to either increase or decrease the protein's activity.64
These active sites can be even smaller than the nanoscale, on the order of
angstroms (or one-tenth as small as a nanometer). 65 But the pharmaceutical
particulates and degradable devices that are approved by the FDA and go
on to be successful products are those that survived the FDA's regulatory
62. FDA Nanotechnology FAQ, supra note 1.
63. Id.
64. An active site is the site on the protein where important activity, such as catalysis of a chemi-
cal reaction, takes place. Often, the material upon which an enzyme acts (called a "substrate") will fit
into the active site, triggering the protein to perform its normal function. In simplified form, one can
envision this mechanism as a "lock and key" model, where the protein is the lock and the substrate that
fits into its active site is the key that "unlocks" the protein's activity. Therefore, many researchers work
on designing new substrates that would fit in the active site and take the place of the usual substrate.
The new substrate could either cause the protein to become inactive or less efficient than the normal
substrate (which would be useful if the protein's normal function somehow makes a person ill) or it
could increase the protein's efficiency (which would be useful if the protein normally functions to the
benefit of the person's health).
65. An angstrom is 1010 meters, where a nanometer is l0 9 meters; an angstrom is denoted by the
symbol A. See, e.g., Young Mi Kim & Daniel M. Ziegler, Size Limits of Thiocarbamides Accepted as
Substrates by Human Flavin-Containing Monooxygenase 1, 28 DRUG METABOLISM & DISPOSITION
1003, 1005 (2000) (providing examples of compounds that about are 4A in width and 10A in length and
fit into a protein active site).
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process-had safety issues arisen due to properties resulting from the prod-
uct's nanoscale size, that product theoretically would not have received
FDA approval. The fact that some products successfully withstood FDA
review does not mean that all nanotechnology-related products will like-
wise be able to withstand such review.
Finally, the FDA's regulatory measures for drugs and medical devices
are much more rigorous than for other types of products, such as cosmetics
and food supplements, that are just as likely to contain nanomaterials. Any
doubts expressed about the adequacy of the FDA's regulatory scheme be-
come even more pressing once one considers that the FDA has little to no
regulatory power over these types of products-products that, if they con-
tain nanomaterials, present the same hazards that exist for pharmaceutical
or medical device products. 66
For example, some of the most prominent nanotechnology products on
the U.S. market are cosmetics, 6 7 which make up more than 15% of the
nanotechnology-product market.68 These include, for example anti-wrinkle
creams such as L'Oreal RevitaLift Double Lifting treatment, which con-
tains "nanosomes" of Pro-Retinol A;69 Lanc6me's Hydra Zen cream, which
contains "nano-encapsulated Triceramides;" 70 and Zelens's name-brand
face cream, which contains C60 molecules. 71 Although cosmetics ostensibly
fall under the FDA's regulatory umbrella, they are primarily regulated by
the manufacturers themselves. 72 Indeed, with the exception of color addi-
tives, the FDA has no statutory authority to subject cosmetic products to
66. Although the FDA currently does not exercise much regulatory oversight over these types of
nanotechnology-related products, this note argues that it is possible for the FDA to do so. For instance,
the FDA could use its Office of Combination Products to regulate cosmetics and soaps containing
nanomaterials; further, the FDA could strictly enforce its own labeling requirements to promote ade-
quate research into the safety hazards of nanomaterials. These proposals are put forth in more detail
below. See infra notes 156-161 & 166-171 and accompanying text.
67. TAYLOR, supra note 22, at 27.
68. As of April 6, 2008, the Project on Emerging Nanotechnologies had identified a total of 607
nanotechnology-related products, and ninety-five were categorized under "cosmetics." Project on
Emerging Nanotechnologies, Nanotechnology Consumer Products Inventory, http://www.nanotech
project.org/inventories/consumer/ (last visited Apr. 6, 2008).
69. Liesl Schillinger, Smart Enough To Understand Your Moisturizer?, N.Y. TIMES, Dec. 22,
2005, at G3.
70. Lanc6me Paris, HydraZen Cream for Normal and Combination Skins, http://www.lancome-
usa.com/skincare/moisturizers/hydra-zen-cream.htm (last visited Apr. 6, 2008).
71. Project on Emerging Nanotechnologies, Zelens Fullerene C-60 Night Cream, http://www.nano
techproject.org/inventories/consumer/browse/products/5266/# (last visited Apr. 6, 2008). The C6o
molecule in Zelens cream is the same molecule that has been shown to bind to and deform DNA. See
Zhao et al., supra note 32.
72. U.S. Food & Drug Admin., FDA Authority Over Cosmetics, http://www.cfsan.fda.gov/-dms/
cos-206.html (last visited Apr. 6, 2008) [hereinafter FDA Authority Over Cosmetics].
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pre-market oversight. 73 The FDA states that "[m]anufacturers are not re-
quired to register their cosmetic establishments, file data on ingredients, or
report cosmetic-related injuries to [the] FDA.' 74 The FDA cannot authorize
a cosmetic product recall, and must depend in large part on the manufac-
turer to voluntarily remove a dangerous product from the marketplace. 75
Instead, the FDA attempts to use its misbranding authority to encourage
proper substantiation of product safety. If the FDA concludes, through its
own examination, that a particular cosmetic product is not safe, the best it
can do is use its labeling authority to inform the consumer: "Warning-The
safety of this product has not been determined. '76 Products that combine
cosmetics and drugs (sometimes called "cosmeceuticals") may slip through
the regulatory cracks, because although the FDA claims that "[s]uch prod-
ucts must comply with the requirements for both cosmetics and drugs,' 77
the fact of the matter is that cosmetics that claim to contain nanoparticles
"intended for use in the diagnosis, cure, mitigation, treatment, or preven-
tion of disease [or] articles (other than food) intended to affect the structure
or any function of the body of man or other animals"'78 have not been sub-
jected to pre-market review.
In addition to cosmetics, nanotechnology-related whole foods, gener-
ally recognized as safe (GRAS) food ingredients, food packaging, and die-
tary supplements are also generally not subjected to pre-market review. 79 If
a dietary supplement "presents a significant or unreasonable risk of illness
or injury" then the FDA can take the product off the market via court order,
but it has no power to regulate the products prior to their release on the
market. 80 Food additives that a manufacturer falsely claims are GRAS may
be subjected to pre-market review, but the manufacturer is not required to
seek FDA review or to notify the FDA of its marketing plan if the manu-
facturer believes the substance is GRAS. 81 Further, although the Code of
Federal Regulations contains a list of substances deemed GRAS by the
73. TAYLOR, supra note 22, at 28.
74. FDA Authority Over Cosmetics, supra note 72.
75. See 21 C.F.R. §§ 7.40-7.59 (2007) (dealing with recalls generally).
76. Id. § 740.10(a).
77. The intended use is established by (1) product claims, such as through advertising, product
labeling, or other promotional materials, (2) consumer perception, and (3) the inclusion of drug ingredi-
ents, which is established if the ingredients have a "well known (to the public and industry) therapeutic
use." U.S. Food & Drug Admin., Is it a Cosmetic, a Drug, or Both? (or Is It Soap?),
http://www.cfsan.fda.gov/-dms/cos-218.html (last visited Apr. 6, 2008) (emphasis added).
78. 21 U.S.C. § 321(g)(l)(B)-(C) (2000).
79. Whole foods that incorporate nanotechnology through genetic modification, however, may be
subjected to review. TAYLOR, supra note 22, at 31.
80. 21 U.S.C. § 342(f); TAYLOR, supra note 22, at 32-33.
8 1. See TAYLOR, supra note 22, at 34.
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FDA, the regulations only rarely contain any reference to safety data spe-
cific to a material's size.82 This is no abstract concern, as companies such
as Nestle, Kraft, Heinz, and Unilever are investing in food-related
nanotechnology research and development-there are already more than
400 companies applying nanotechnology to food in more than 150 different
applications. 83 Some of these products are already on the market. For in-
stance, one company is using silver nanoparticles in its food containers as
an antimicrobial to "reduce the growth of microorganisms, '84 and at least
forty dietary supplements containing nanoscale ingredients such as iridium,
copper, and "nanocolloidal silicate mineral[s]" are available for purchase.
85
But even for products that receive the most searching FDA review,
such as pharmaceutical compounds, nanotechnologies create difficulties.
The first of these challenges is a direct result of the way in which the FDA
is organized. Assigning a given product to a center is not as easy as it may
appear at first blush. Combination products, or products that contain any
combination of a drug, a device, and a biological product, are on the rise.
86
82. See, e.g., 21 C.F.R. pt. 182 (2007).
83. Sean Roach, Most Companies Will Have To Wait Years for Nanotech's Benefits,
FOODPRODUCTIONDAILY.COM, Aug. 21, 2006, http://www.foodproductiondaily.com/news/ng.asp?n=
69974-nanotechnology-packaging-nano-applications; see Bamaby J. Feder, Engineering Food at Level
of Molecules, N.Y. TIMES, Oct. 10, 2006, at C1, C2.
84. For example, Sharper Image is currently marketing the FresherLonger Miracle Food Storage
Containers, which use silver nanoparticles "because silver in microscopic particle form is a safe, medi-
cally proven antibacterial agent that fights the growth of mold and fungus." Press Release, Sharper
Image, Sharper Image Introduces FresherLongerTM Miracle Food Storage Containers (Mar. 8, 2006),
available at http://www.nsti.org/press/PRshow.html?id=867. In microscopic particle form, silver may
be safe, but there is no mention of whether silver nanoparticles are safe, or if the particles used in the
product are actually nanoscale particles. In addition, Sharper Image does not mention the possibility
that nanoparticles are used in the product on the FresherLonger product webpage. Sharper Image,
FresherLongerTM Miracle Food Storage, http://www.sharperimage.com/us/en/catalog/productdetails/sku
__ZN020 (last visited Apr. 6, 2008). This highlights the importance of proper labeling, as a consumer
cannot exercise his or her choice to avoid or limit nanoparticle exposure if he or she will not even be
informed by the manufacturer that the product contains nanoparticles.
85. Project on Emerging Nanotechnologies, Supplements, http://www.nanotechproject.org/inven
tories/consumer/browse/categories/foodbeverage/supplements/ (last visited Apr. 6, 2008) (listing
company descriptions for Nanoceuticals Microhydrin Products and various "Meso" formulations,
including formulations containing nanosized iridium, copper, gold, silver, platinum, titanium, and
palladium).
86. A combination product, as defined in 21 C.F.R. § 3.2(e), includes:
(1) A product comprised of two or more regulated components, i.e., drug/device, bio-
logic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or other-
wise combined or mixed and produced as a single entity; (2) Two or more separate products
packaged together in a single package or as a unit and comprised of drug and device products,
device and biological products, or biological and drug products; (3) A drug, device, or bio-
logical product packaged separately that according to its investigational plan or proposed la-
beling is intended for use only with an approved individually specified drug, device, or
biological product where both are required to achieve the intended use, indication, or effect
and where upon approval of the proposed product the labeling of the approved product would
need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of
administration, or significant change in dose; or (4) Any investigational drug, device, or bio-
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Because "technological advances continue to merge therapeutic products
and blur the historical lines of separation between [the] FDA's medical
product Centers," any one of the three medical product centers (CDER,
CBER, and CDRH) could potentially claim regulatory jurisdiction over a
combination product. 87 As each center differs in its regulatory scheme, the
destination of a given product can have important consequences for the
manufacturer. For example, the application fees differ significantly, rang-
ing from $281,600 for a pre-market medical device application to $896,200
for a drug application that requires clinical data. 88 There are statutory dif-
ferences in approval times, and anecdotal evidence suggests that manufac-
turers often believe their product has a better chance of securing approval
in one center versus another.89 Differences in clinical testing also come into
play. For example, CDER and CBER usually require randomized, placebo-
controlled studies for certain products, whereas CDRH will allow a variety
of different study designs. 90 This is key for the manufacturer, who is look-
ing to minimize costs, but it also has implications for public safety, as
products that should be subjected to the strongest possible review may
avoid that review by being assigned to a different center.
The FDA formed the Office of Combination Products, or OCP, in De-
cember of 2002 to address these challenges. 91 The OCP is generally
charged with overseeing pre-market review of combination products and
attempting to maintain consistency in the post-market regulation of those
products.92 It also works with CBER, CDER, and CDRH to develop regu-
lations and guidelines for combination products. When a combination prod-
uct application is filed at the FDA, the OCP assigns the product to one of
the medical product centers based on the product's Primary Mode of Ac-
tion (PMOA).93 It does so in part by considering the applicant's "request
logical product packaged separately that according to its proposed labeling is for use only
with another individually specified investigational drug, device, or biological product where
both are required to achieve the intended use, indication, or effect.
87. U.S. Food & Drug Admin., Overview of the Office of Combination Products,
http://www.fda.gov/oc/combination/overview.html (last visited Apr. 6, 2008) [hereinafter Overview of
OCP].
88. Medical Device User Fee Rates for Fiscal Year 2007, 71 Fed. Reg. 43,784 (Aug. 2, 2006);
Prescription Drug User Fee Rates for Fiscal Year 2007, 71 Fed. Reg. 43,780 (Aug. 2, 2006).
89. John Miller, Note, Beyond Biotechnology: FDA Rlation of Nanomedicine, 4 COLUM. SCI.
& TECH. L. REV. 2, 23 (2003), http://www.stlr.orgfhtml/volume4/miller.pdf (citations omitted).
90. Id. (citing LEWIN GROUP, OUTLOOK FOR MEDICAL TECHNOLOGY INNOVATION: WILL
PATIENTS GET THE CARE THEY NEED? 30 (2001)).
91. The OCP was created in the Medical Device User Fee Modernization Act of 2002 § 204, 21
U.S.C. § 353(g) (Supp. IV 2004).
92. Overview of OCP, supra note 87.
93. 21 U.S.C. § 353(g)(1).
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for designation," or RFD. 94 Under 21 C.F.R. § 3.7, the applicant files an
RFD setting forth her recommendation as to which center should have pri-
mary jurisdiction over her product. The recommendation is based on her
perception of the product's PMOA.95 The OCP does not have to follow the
recommendation, but as a practical matter, the OCP usually does-an ap-
plicant's recommendation is actually followed 72% of the time. 96 This
symmetry likely stems in part from the fact that if the OCP fails to make its
own recommendation within sixty days of the RFD, the applicant's rec-
ommendation will be followed by default.97 Therefore, the accuracy of the
initial identification of a product's PMOA may have far-reaching conse-
quences.
Until recently, there was little to assist an applicant in determining a
combination product's PMOA. The FDA did not provide a formal defini-
tion, and the very nature of combination products often made it difficult to
figure out which action was "primary." 98 The director of the OCP, Mark
Kramer, explained that there are "products that combine two different
things, such as a drug and a device, [and in the future nanotechnology may
lead to] ... products that perform two functions; for example, a single en-
tity's acting as both a device and a drug." 99 In these cases, the combination
product may have two different modes of action that are of equal impor-
tance. Therefore, in 2005, the FDA attempted to clarify its regulations by
providing a definition for PMOA. The PMOA is "the single mode of action
of a combination product that provides the most important therapeutic ac-
tion of the combination product. The most important therapeutic action is
the mode of action expected to make the greatest contribution to the overall
intended therapeutic effects of the combination product."lOO When each
mode of action appears equally important, the applicant (or if no recom-
mendation is provided, the OCP) is to follow an algorithm to determine the
94. This recommendation is completely voluntary, but the FDA recommends filing an RFD
whenever the classification or assignment of a product is unclear or in dispute. Failure to do so may
cause delay, as the FDA will stay any established time periods for agency action during the pendency of
the review. 21 C.F.R. § 3.10 (2007).
95. 21 C.F.R. § 3.7(c)(3).
96. 21 C.F.R. § 3.8(b); Suzanne O'Shea, Product Classification Officer, U.S. Food & Drug
Admin., Address at AvaMed MTL Con erence: Practical Issues in Combination Products: Primary
Mode of Action & Request for Designati6n (May 25, 2006), slides available at http://www.fda.gov/oc/
combination/presentations/advamed files/.
97. 12 C.F.R. § 3.8(b).
98. Definition of Primary Mode of Action of a Combination Product, 70 Fed. Reg. 49,848 (Aug.
25, 2005).
99. Erik Swain, Forging New Regulatory Pathways at FDA, MED. DEVICE & DIAGNOSTIC INDUS.,
Sept. 2004, at 58, 60, available at http://www.devicelink.com/mddi/archive/04/09/015.html.
100. 21 C.F.R. § 3.2(m) (emphasis added).
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PMOA. The algorithm dictates that the product will be assigned to the cen-
ter that regulates products posing "similar questions of safety and effec-
tiveness;" if no such combination product already exists, the product will
be assigned to the center with the most expertise as to those safety and
effectiveness issues. 101
Two problems arise with the OCP's method of determining an appro-
priate regulatory center. First, many have criticized the PMOA algorithm as
being entirely too subjective, leading to a lack of consistency, predictabil-
ity, and transparency. 102 One common example of this subjectivity illus-
trates the point nicely. Common sense dictates that a drug-eluting stent and
a drug-eluting disc should be assigned to the same regulatory center, as
both are implantable devices designed for drug release. 103 However, be-
cause the stent's PMOA would be identified as "opening an artery," while
the disc's PMOA would be identified as "providing chemotherapy to a
tumor," the FDA would route the drug-eluting stent application to the Cen-
ter for Devices and Radiological Health and the drug-eluting disc applica-
tion to the Center for Drug Evaluation and Research. 104
The subjectivity of center assignment is likely to be more pronounced
in nanotechnology combination products for two reasons: first, the FDA is
still relatively unfamiliar with the implications of products created on the
nanoscale and may not be able to determine a nanotechnology product's
PMOA with consistency or accuracy; 105 and second, the attraction of
nanotechnology products is due in part to their potential combinatorial
nature, making it likely that a higher percentage of nanotechnology prod-
ucts will be classified as combination products as compared to non-
nanotechnology products. 106 This in turn makes it more likely that
101. 21 C.F.R. § 3.4(b).
102. Mark Lavender, Note, Regulating Innovative Medicine: Fitting Square Pegs in Round Holes,
2005 DUKE L. & TECH. REV. 1, 36, http://www.law.duke.edu/joumals/dltr/articles/pdf/2005dltr000
.pdf (citing Risk Should Drive Combo Product Jurisdiction, Industry Recommends, DEVICES &
DIAGNOSTICS LETTER (U.S. Food & Drug Admin., Rockville, Md.), Dec. 2, 2002).
103. To elute something is to wash it out of a material; here, a drug would first be adsorbed onto
either a stent or a disc, and when the stent or disc is placed inside the body the drug "washes out" or
dissolves into the person's system. The word "stent" refers a "short narrow metal or plastic tube often in
the form of a mesh that is inserted into... an anatomical vessel (as an artery or a bile duct) ... to keep
a previously blocked passageway open." MERRIAM-WEBSTER'S COLLEGIATE DICTIONARY, supra note
49, at 405, 1222.
104. O'Shea, supra note 96.
105. In fact, the FDA recently held a public meeting to get input and to learn more about nanotech-
nology and to learn "whether there are new or emerging scientific issues that should be brought to [the]
FDA's attention, including issues relating to safety of nanotechnology materials." Food and Drug
Administration-Regulated Products Containing Nanotechnology Materials; Public Meeting, 71 Fed.
Reg. 46,232, 46,232 (Aug. 11, 2006) (emphasis added).
106. See Swain, supra note 99.
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nanotechnology product applications will be routed through the OCP, and
thus that those applications could potentially be assigned to an inappropri-
ate center or that similar applications will be routed inconsistently.
Second, the only combination products addressed under current regu-
lation are those that combine some aspect of a drug, a device, or a biologic.
No guidance or consideration is given to unofficial combination products.
For example, L'Oreal's anti-wrinkle cream RevitaLift has been classified
as a cosmetic despite the fact that it contains "nanosomes of Pro-Retinol
A,"'107 and the FDA has very little pre-market regulatory power over cos-
metics. 108 One can imagine other products, such as nano-engineered foods
or dietary supplements, which could create confusion as to whether the
product is a food or a drug. These products are difficult to define, and they
raise many of the same concerns that prompted the formation of the OCP in
the first place.
The FDA must do something to close its regulatory gaps before the
public health is adversely affected. Other agencies have recognized that
nanotechnology requires something new, and have adapted in an attempt to
fulfill their regulatory duties. One such agency is the U.S. Patent and
Trademark Office, or USPTO. Many nanotechnology products are subject
to both USPTO and FDA scrutiny, as inventors frequently attempt to se-
cure patent protection prior to submitting their product for FDA approval.
Despite the fact that these two agencies often work in tandem, however,
their current approaches to nanotechnology-related inventions are at odds.
Obviously, the goals of the FDA and the USPTO are quite different-the
FDA is concerned primarily with public health, whereas the USPTO fo-
cuses on limiting its grant of patent protection to those inventions that meet
the statutory requirements. But these differences do not preclude the FDA
from adapting USPTO methods that are appropriate to its end, nor do they
preclude the FDA from taking advantage of information generated by the
USPTO.
107. See supra note 69 and accompanying text.
108. See Letter from David Rejeski, Project on Emerging Nanotechnologies, Woodrow Wilson
Int'l Ctr. for Scholars, to Division of Dockets Management, Food & Drug Admin. (July 19, 2006),
available at http://www.fda.gov/ohrms/dockets/dockets/06nOlO7/06N-0107-EC7-Attach-l.pdf; TAY-
LOR, supra note 22, at 28.
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IV. THE USPTO's CURRENT APPROACH
Title 35 of the United States Code provides that a patentee must meet
various criteria before her invention will receive patent protection. 109 First,
the inventor has to show that her invention falls within one of the catego-
ries of patentable subject matter, namely that her invention is a "process,
machine, manufacture, or composition of matter, or any ... improvement
thereof."'10 Next, the inventor must show that her invention is at least
minimally useful."I ' She must enable her invention by describing it with
enough detail that another inventor of average skill in the applicant's field
(a "person having ordinary skill in the art") can make the invention without
undue experimentation. 112 She must provide an adequate written descrip-
tion, set forth her perception of the "best mode" or method of making the
invention, and particularly point out and distinctly claim her invention un-
der the "definiteness" requirement.' 13 Finally, the invention must be novel
and non-obvious.11 4 Only if and when the inventor satisfies all of these
criteria will she receive a limited monopoly right in her invention.
Of course, the USPTO does not take it on faith that the patent appli-
cant will satisfy these criteria. Each patent application undergoes a rigorous
examination by a patent examiner, a procedure that often takes years.
115
The USPTO is structurally organized to ensure that it routes each applica-
tion to the patent examiner best equipped to determine whether the inven-
tion meets the statutory requirements. The patent examiners are divided
amongst seven technology centers, each of which is dedicated to a broadly-
109. 35 U.S.C. §§ 101-112 (2000). A detailed discussion of patentability requirements is outside
the scope of this note; for a rather more detailed explanation, visit U.S. Patent & Trademark Office,
General Information Concerning Patents, http://www.uspto.gov/web/offices/pac/doc/general/index.html
(last visited Apr. 21, 2008).
110. 35 U.S.C. § 101.
111. Id. The utility requirement does not preclude the USPTO from granting patent protection to,
for example, an invention that deceives a consumer. See Juicy Whip, Inc. v. Orange Bang, Inc., 185
F.3d 1364, 1366-67 (Fed. Cir. 1999).
112. 35 U.S.C. § 112.
113. Id.
114. Id. §§ 102-103. The statute prevents an inventor from receiving protection for something that
was already invented by another, or from receiving protection for that which would have been obvious
to a person having ordinary skill in the art at the time of his invention.
115. In 2007, the average patent was pending before the USPTO for almost thirty-two months. This
time has increased from past years-in 2004, for example, a patent was pending on average for about
twenty-eight months. UNITED STATES PATENT AND TRADEMARK OFFICE, PERFORMANCE AND
ACCOUNTABILITY REPORT: FISCAL YEAR 2007, at 16 (2007), available at http://www.uspto.gov/web/
offices/com/annual/2007/2007annualreport.pdf. The increase is undoubtedly due in part to the increase
in patent applications being filed each year (355,418 in 2003 to 467,243 in 2007). Id. at 109 tbl. 1.
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defined technology. 116 For example, examiners within Technology Center
1600 will examine patent applications relating to biotechnology and or-
ganic chemistry."l 7 Each technology center is further divided into four to
eight work groups, which are further divided into art units.1 18 The art units
are the smallest subdivisions within the USPTO, and each art unit consists
of about ten to twenty examiners. 119
Once a patent application is received, it is assigned to an art unit. The
art unit's supervisory patent examiner then assigns the application to a
specific examiner. The patent applications are also assigned a primary clas-
sification number and a more specific sub-classification number. 120 These
classification numbers serve two functions: first, they assist the USPTO in
properly routing the patent applications within the agency, and second, they
assist examiners in locating relevant "prior art" (references that relate to the
invention and may prove that the invention is obvious or not novel). 121 In
addition to the primary classification, the examiner will also list other rele-
vant classification and sub-classification numbers on the face of the patent
application for purposes of cross-referencing. When the patent application
is published, the primary classification/sub-classification number is called
the "PR" or Primary Classification; additional classifications are known as
"SR" or Secondary Classifications. Once the patent application is going to
issue as a patent, the principle classification is an "OR" or Original Classi-
fication; the secondary classifications are known as "XR" or Cross Refer-
ence Classifications. 122 Each art unit is assigned dominion over particular
PR groups. The limitations as to which applications are routed to a given
art unit allow each examiner to gain substantial expertise in his or her spe-
cialized area. 1
23
116. Bruce Kisliuk, Group Director of Tech. Ctr. 1600, U.S. Patent & Trademark Office, Presenta-
tion at NC Nanotech 2006: Nanotechnology-Related Issues at the United States Patent and Trademark
Office (Mar. 9, 2006) [hereinafter Nanotechnology-Related Issues at the USPTO], slides available at
https://files.changemywebsite.com/684462/doc/BruceKisluik.pdf.
117. The other technology centers are TC 1700, Chemical and Materials Engineering; TC 2100,
Computer Architecture, Software, and Information Security; TC 2600, Communications; TC 2800,
Semiconductors, Electrical and Optical Systems and Components; TC 3600, Transportation, Construc-
tion, Electronic Commerce, Agriculture, National Security and License and Review; and TC 3700,
Mechanical Engineering, Manufacturing, Products. There is also a technology center devoted to design
patents, TC 2900. U.S. Patent & Trademark Office, Patent Technology Centers, http://www.uspto.gov/
web/info/pat-tech.htm (last visited Apr. 6, 2008).
118. E-mail from Bruce Kisliuk, Group Director of Tech. Ctr. 1600, U.S. Patent & Trademark
Office, to Jessica Fender, Student, Chicago-Kent College of Law (Jan. 28, 2007, 20:15 CST) (on file
with the Chicago-Kent Law Review); Nanotechnology-Related Issues at the USPTO, supra note 116.
119. E-mail from Bruce Kisliuk, supra note 118.
120. USPTO, OVERVIEW OF THE U.S. PATENT CLASSIFICATION SYSTEM (USPC) 1-1 (2006).
121. Id. at 1-2.
122. Id. at 1-4 to 1-5.
123. E-mail from Bruce Kisliuk, supra note 118.
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Like the FDA, the USPTO has been affected by the onslaught of
nanotechnology-related inventions-by some measures, the USPTO issued
upwards of 8600 nanotechnology-related patents in 2003.124 Nanotechnol-
ogy-related patent applications presented unique challenges to the
USPTO's organizational scheme. When these applications first began ap-
pearing, the USPTO ignored the "nano" aspect of the inventions, and as-
signed the applications to art units based upon their underlying
technologies. 125 This technique provides insight as to why almost 800 dif-
ferent patent examiners were assigned nanotechnology-related applications
between 2001 and 2003-a number representing almost one-fourth of the
total primary patent examiners in the USPTO. 126 Not surprisingly, data like
these raised the concern that examiners were not accumulating much-
needed expertise in the nanotechnology field. 127
The problem, however, is that there are serious difficulties present in
classifying nanotechnology-related applications. The only unifying theme
in nanotechnology is scale. In other words, "the use or inclusion of struc-
tural components or objects that are nanoscale occurs in a wide range of
technologies, including many with no common ground or common proper-
ties attributable to their nano-sized dimension."' 28 This diversity is illus-
trated by looking at PR classifications: nanotechnology-related patents can
be found in more than 200 different classes. 129 Complicating matters fur-
ther, the field continues to lack a unified nomenclature. Some nanotechnol-
ogy-related applications do not include recognized nanotechnology terms,
either because the generic terms do not best describe the invention or be-
cause the applicant may write the patent claims to "hide" them from the
competition. 130 Therefore, simply identifying nanotechnology-related ap-
plications can be quite difficult.
124. PRESIDENT'S COUNCIL OF ADVISORS ON SCI, & TECH., THE NATIONAL NANOTECHNOLOGY
INITIATIVE AT FIVE YEARS: ASSESSMENT AND RECOMMENDATIONS OF THE NATIONAL
NANOTECHNOLOGY ADVISORY COUNCIL 15 (2005) available at http://www.nano.gov/FINALPCAST
_NANO_REPORT.pdf, see Dora Marinova & Michael McAleer, Nanotechnology Strength Indicators:
International Rankings Based on US Patents, 14 NANOTECH. RI, R2 (2003), available at
http://www.iop.org/EJ/toc/0957-4484/14/1.
125. Blaise Mouttet, Nanotech and the U.S. Patent & Trademark Office: The Birth of a Patent
Class, 2 NANOTECH. L. & BuS. 260, 260 (2005).
126. Bhaven N. Sampat, Examining Patent Examination: An Analysis of Examiner and Applicant
Generated Prior Art 25 (2004) (unpublished NBER working paper, on file with the Chicago-Kent Law
Review).
127. Id.
128. M. Henry Heines, "'Nano-Aerobics" and the Patent System, 4 NANOTECH. L. & BUS. 335, 338
(2005).
129. Sampat, supra note 126, at 25.
130. Raj Bawa, Nanotechnology Patenting in the US, I NANOTECH. L. & BuS. 31, 38 (2004).
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The USPTO attempted to face the challenges of nanotechnology, rec-
ognizing that its regulatory scheme had to adapt, as it has in the past, to
address these concerns. First, the USPTO began identifying nanotechnol-
ogy-related applications and patents in November of 2001. In 2004, the
agency officially created Class 977/DIG. 1, a new nanotechnology CR clas-
sification. 131 At that time, the USPTO provided a working definition for
those patents and applications that met the requirements of Class 977. It
also provided a glossary of common nanotechnology-related terms that
examiners might encounter (e.g. "nanotube," "quantum dot," and "artificial
atom"). 132 Finally, in November of 2005 the USPTO divided the digest into
263 specific sub-classifications. 133 As of April 1, 2008, almost 5000 pat-
ents and more than 2500 published patent applications were cross-
referenced under Class 977.134
To be cross-referenced under Class 977, the patent must "relate[] to
nanostructure." 135 Not only does the invention have to relate to nanostruc-
ture, but that nanostructure must "possess[] a special property, provide[] a
special function, or produce[] a special effect that is uniquely attributable to
the structure's nanoscale physical size." 136 What does it mean to possess a
special property or function? The USPTO further explains:
Special properties and functionalities should be interpreted broadly, and
are defined as those properties and functionalities that are significant,
distinctive, non-nominal, noteworthy, or unique as a result of the nano-
scale dimension. In general, differences in properties and functionalities
that constitute mere differences of scale are insufficient to warrant inclu-
sion of the subject matter in Class 977.137
To provide context for this statement, the USPTO provides two non-
limiting examples. First, a conductor that possesses "substantially the same
electrical properties" on the nanoscale as it possesses on a larger scale
would not be classified as Class 977, but a conventional conductor that
131. Robeson, supra note 8, at 2.
132. U.S. Patent & Trademark Office, Class 977, http://www.uspto.gov/web/offices/opc/documents
/977_classdef.pdf (last visited Apr. 6, 2008) [hereinafter Class 977].
133. Robeson, supra note 8, at 3.
134. U.S. Patent & Trademark Office, US Patent Full-Text Database Manual Search,
http://patft.uspto.gov/nctahtml/PTO/search-adv.htm (searching for CCL/977/S) (last visited Apr. 6,
2008); U.S. Patent & Trademark Office, US Published Application Full-Text Database Manual Search,
http://appftl .uspto.gov/netahtml/PTO/search-adv.html (searching for CCL/977/$) (last visited Apr. 6,
2008). The patents were current through April 1, 2008; the patent applications were current through
April 3. 2008.
135. Class 977, supra note 132, at 1.
136. Id.
137. Id. (emphasis added).
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exhibits quantum confinement 10 8 or superconductivity1 39 when created on
the nanoscale would be classified under Class 977.140 Similarly, a catalyst
that becomes more reactive on the nanoscale would not be classified under
Class 977, unless the increased reactivity was beyond that following natu-
rally from the increase in specific surface area.141
Class 977 also exempts some types of inventions outright. For in-
stance, chemical and biological structures are generally classified else-
where unless they have a particular "nanostructural assemblage" that alters
their chemical or physical properties. 142 Otherwise, almost every chemical
or biological structure would "relate to nanostructure." Apparatuses that
manufacture nanoscale matter "top down" instead of "bottom up" are gen-
erally excluded, 143 as are inventions that make use of electromagnetic ra-
diation having a wavelength between 1-100 nm. 144 Exclusions such as
these ensure that the inventions cross-referenced under Class 977 do in fact
relate to nanotechnology in a meaningful sense.
The USPTO did not stop with creating a new classification scheme.
Although nanotechnology-related patent applications do not have their own
unique art unit 145 the USPTO has taken steps to ensure that its patent exam-
iners can get the support that they need to become proficient in the quirks
of nanotechnology. First, every technology center has a number of examin-
138. For an explanation of quantum confinement, see PETER Y. YU & MANUEL CARDONA,
FUNDAMENTALS OF SEMICONDUCTORS 470-71 (3d rev. ed. 2005).
139. Superconductivity is "a complete disappearance of electrical resistance in a substance[, espe-
cially] at very low temperatures." MERRIAM-WEBSTER'S COLLEGIATE DICTIONARY 1178 (10th ed.
2001). See generally MICHAEL TINKHAM, INTRODUCTION TO SUPERCONDUCTIVITY (2d ed. Dover 2004)
(1996).
140. Class 977, supra note 132, at 2.
141. Id. Specific surface area is the surface area of an object divided by its volume. As the volume
of a particle shrinks, the ratio of surface area to volume increases. For instance, a 3 cm by 3 cm cube
will have a surface area of 54 cm 2 and a volume of 27 cm3-a 2:1 ratio of surface area to volume. If the
cube shrinks to a 2 cm by 2 cm cube, its surface area will be 24 cm 2 and its volume will be 8 cm 3-a
ratio of 3:1. If the cube shrinks down to the nanoscale, its surface area to volume ratio will naturally be
much higher-any increased reactivity will generally not be a result of special nanoscale functionality.
However, if the particle had a reactivity much greater than one would predict from the specific surface
area, it could properly be classified under Class 977 (assuming it otherwise fit the classification defini-
tion).
142. Id. at 1. Thus, a fullerene or a nanotube would still be cross-referenced under Class 977.
143. For an illustration of "top down" versus "bottom up" manufacturing in the nanotechnology
context, see ROYAL SOC'Y & ROYAL ACADEMY OF ENGINEERING, NANOSCIENCE AND
NANOTECHNOLOGIES 25 (2004), available at http://www.nanotec.org.uk/reportlNano%20report%20200
4%20fin.pdf.
144. Class 977, supra note 132, at 2.
145. Most nanotechnology patents are distributed amongst the following technology centers:
Biotechnology and Organic Chemistry; Chemical and Materials Engineering; Semiconductor, Electri-
cal, Optical Systems; and Mechanical Engineering, Manufacturing, and Products. As of January 2006,
these TCs examined a total of 92% of all nanotechnology-related patent applications. Nanotechnology-
Related Issues at the USPTO, supra note 116.
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ers that specialize in nanotechnology-related applications. 146 Although
theoretically any examiner could be assigned a nanotechnology patent ap-
plication, the majority of the patents are examined by about 100 examin-
ers. 147 Second, the USPTO maintains a non-publicly accessible website for
those examiners who do not feel comfortable with nanotechnology. This
website includes nanotechnology-related search information, outside web
links, and the contact information for seventy patent examiner "points of
contact," or POCs. 148 These POCs are patent examiners who have substan-
tial experience with nanotechnology and have volunteered to assist less-
experienced examiners with their research. Finally, between fifty and 100
patent examiners attend nanotechnology-related training every month. 149
In sum, the USPTO recognized that nanotechnology-related inven-
tions required special attention. It promulgated a working definition of
nanotechnology which was specifically adapted to its administrative pur-
pose. It created a new cross-reference class, thereby enabling patent exam-
iners to gain experience in nanotechnology and assisting the examiners in
identifying useful references. It also established a framework for examiners
to get outside help when they desire it, either through POCs or through
special training sessions. Although the USPTO continues to receive criti-
cism in its handling of nanotechnology-related patent applications,1 50 it has
taken a significant step towards ensuring that it can fulfill its regulatory
role with this new type of technology.
V. USING CLASS 977 TO THE FDA's ADVANTAGE
When one considers that the scanning tunneling microscope was in-
vented in the 1980s,151 the USPTO's delay in classifying nanotechnology-
related patents until 2001 may appear overly long. Compared to the FDA,
however, the USPTO has moved relatively quickly. The USPTO's classifi-
cation scheme should both highlight the weak points in the FDA's regula-
tory oversight and provide a guiding light for the FDA as it modifies its
146. E-mail from Bruce Kisliuk, supra note 118.
147. Id.; see Where Science and Law Meet: Nanotechnology and Intellectual Property Issues,
MONTHLY FEATURE (Nat'l Cancer Inst. Alliance for Nanotech. in Cancer, Bethesda, M.D.), Oct. 2006,
at 1, 3, available at http://nano.cancer.gov/news center/monthly-feature_2006_oct.pdf.
148. Where Science and Law Meet, supra note 147; E-mail from Bruce Kisliuk, supra note 118.
149. Often, the training takes place at the Atlantic Nano Forum or the American Society of Me-
chanical Engineers Nanotech Boot Camp. In addition, there are many other nanotechnology training
seminars. E-mail from Bruce Kisliuk, supra note 118.
150. E.g., Jon Van, Slow Patent Process Hurts Nanotech Progress, CHI. TInB., Oct. 29, 2006, § 5,
at 1, 12.
151. Baird & Shew, supra note 3, at 145, 145-46.
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current approach-but right now, the information generated by the USPTO
is going to waste.
By cross-referencing an application or a patent under Class 977, the
USPTO provides public notice that the invention has novel properties
which are not the natural result of small scale. But that same invention,
once submitted to the FDA for approval, will be treated exactly as its large-
scale counterpart. Worse, if the invention is a cosmetic, soap,' 52 or other-
wise GRAS, it will be placed on the market with little to no FDA oversight.
The fact that two regulatory agencies with different mandates might regu-
late particular products differently is not surprising, but in this case it is
unacceptable. It is the FDA, not the USPTO, that is charged with looking
after the public health and safety; yet when the USPTO provides the
equivalent of a warning sign-Class 977--on a patented product, the FDA
continues to state that its current regulatory scheme should be adequate.
The USPTO's Class 977 label can and should be used by the FDA to
identify products that warrant stricter regulatory controls. 153 Many pharma-
ceutical products that are patented at the USPTO will not be cross-
referenced under Class 977, since the class definition exempts chemical
and biological structures that do not have unique nanotechnology-related
properties. 154 Medical devices are more likely to be classified under Class
977,155 but as already noted, medical devices and pharmaceuticals are two
152. The FDA has a very particular definition of "soap" and a soap product that "consists of deter-
gents or primarily of alkali salts of fatty acids and is intended not only for cleansing but also for other
cosmetic uses, such as beautifying or moisturizing" will be treated as a cosmetic. If the soap makes no
claims to beauty treatment but instead makes a medical claim (such as curing dandruff) it may be
regulated as a drug. Soap that makes no claim beyond cleansing is regulated not by the FDA, but by the
Consumer Product Safety Commission. Harold Hopkins, All that Lathers Is Not Soap, FDA CONSUMER
(U.S. Food & Drug Admin., Rockville, M.D.), Feb. 1979, available at http://www.cfsan.fda.gov/
-dms/cos-215.html#update; U.S. Food & Drug Admin., Is it a Cosmetic, a Drug, or Both? (or is it
Soap?), http://www.cfsan.fda.gov/-dms/cos-218.html (last visited Apr. 6, 2008) [hereinafter Cosmetic,
Drug, or Soap].
153. See, e.g., Petition from the Int'l Ctr. for Tech. Assessment, et al., to the U.S. Food & Drug
Admin. 64-68 (May 17, 2006), available at http://www.fda.gov/ohrms/dockets/dockets/06pO2l0/O6p-
0210-cp00001-01-voll.pdf (arguing that nanotechnology inventions that have received U.S. patent
protection should be considered novel substances, thereby requiring new drug applications prior to FDA
approval). But see Bridget A. O'Leary Smith, Everything New Is Old Again: Patentable Novelty of
Nanoscale Chemical Materials Does Not Imply Newness Under the TSCA and the FDCA, 4
NANOTECH. L. & BuS. 457, 470 (2007) (arguing that "the patentable novelty of nanoscale chemicals is
simply not the proper standard to trigger... [new drug] requirements for them" in part because the
converse is not true, namely, that "a substance that is not new under the Patent Act should not be sub-
ject to health and safety regulation under the FDCA or TSCA," but recognizing that "this is not to say
that nanoscale drugs ... should not be regulated as new drugs under FDCA or that nanoscale chemicals
should not be regulated as new chemical substances under the TSCA").
154. Class 977, supra note 132, at 1.
155. The following query yielded 53 patents on April 6, 2008: CCL/977/S and SPEC/"medical
device." U.S. Patent & Trademark Office, US Patent Full-Text Database Manual Search,
http://patft.uspto.gov/netahtml/PTO/search-adv.htm (last visited Apr. 6, 2008).
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categories of FDA-regulated products that already undergo relatively in-
depth pre-market safety testing. The USPTO's Class 977 label is arguably
somewhat less useful for these products.
On the other hand, the Class 977 label can be quite useful for the FDA
in areas where its regulatory oversight is otherwise at its weakest, such as
in cosmetics and soaps. Inventions like these fall squarely within Class 977.
L'Oreal Paris, for example, holds twenty-seven patents that are cross-
referenced under Class 977.156 Of these, twenty-one contain the words
"cosmetic" or "dermatological" in the title, and another claims to "combat[]
blemishes on and/or ageing of the skin" using a composition that can be
disbursed by polymer nanocapsules. 157 Johnson and Johnson has invested
in a cosmetic composition patent cross-referenced under Class 977,158 as
has Unilever. 159 There are Class 977 patents that claim new body wash
compositions 160 and those that nanosize GRAS compounds. 161 This pro-
vides strong evidence that the Class 977 label effectively identifies a subset
of products that are related to nanotechnology and that are not subject to
FDA pre-market review.
Obviously, the FDA cannot ensure the public safety by simply sub-
jecting Class 977 inventions to stricter scrutiny: not all inventions move
from the USPTO to the FDA; the USPTO issues patents on products that
may pose nanotechnology-related health hazards, but are not cross-
referenced under Class 977; and some products are regulated by the FDA
without the inventor first filing for a patent. Class 977 simply brings into
focus the fact that current FDA standards are inadequate to ensure
nanotechnology product safety, and that valuable information generated by
one agency is being ignored when it could be used to inform the FDA's
next steps.
One of the most important things the FDA can do is to propagate its
own definition of nanotechnology. 162 Not only would a working definition
assist the agency in shaping its policy, but it would assist product manufac-
turers in determining when they must comply with the FDA's existing
regulatory mechanisms. Michael Taylor, of the Project on Emerging
156. Id. (searching "CCL/977/$ and AN/loreal").
157. Id. (searching "CCL/977/$ and AN/loreal and TTL/(cosmetic$ or dermatologic$)"). The
specific patent referred to above is U.S. Patent No. 5,670,487 (filed June 20, 1996).
158. U.S. Patent No. 6,544,531 (filed Nov. 9, 1999).
159. U.S. Patent No. 5,814,343 (filed Feb. 21, 1996).
160. E.g., U.S. Patent No. 6,303,109 (filed Mar. 3, 1999).
161. E.g., U.S. Patent No. 6,001,336 (filed Dec. 29, 1997).
162. This recommendation has been made in some form by a number of groups. E.g., Petition from
the Int'l Ctr. for Tech. Assessment, supra note 153.
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Nanotechnologies, has convincingly argued that the FDA should provide
criteria for two subcategories: "new for legal and regulatory purposes," and
"new for safety evaluation purposes."' 163 He explains:
To guide companies in making what amount to market-entry deci-
sions for their particular products, [the] FDA should promptly establish
criteria for judging when a nanomaterial is "new" for legal and regula-
tory purposes, i.e., for purposes of distinguishing it from versions that
are already listed in [the] FDA's GRAS, food additive and food packag-
ing regulations or that have been reviewed through the Cosmetic Ingre-
dient Review (CIR).... The point is to have a basis for companies to
know when they need to come to [the] FDA prior to marketing, versus
when they can rely for legal and regulatory purposes on the existing ap-
proval, GRAS affirmation or CIR review of the conventional form of the
material ....
[The criteria for "new" for safety evaluation purposes] presumably
would include functional properties that relate to the likelihood that the
safety profile of the nanotechnology version would be different from the
conventional one. Such criteria would be helpful for all categories of
FDA-regulated products as a guide to decisions about the need for toxic-
ity testing beyond what already exists on the conventional form. 16 4
The Class 977 cross-reference should be considered by the FDA and
manufacturers alike to indicate that the product is new for both legal and
regulatory purposes and for safety evaluation purposes. The cross-reference
classification indicates that another governmental agency, while using a
definition of nanotechnology that closely resembles the National
Nanotechnology Institute's definition (which the FDA has not officially
adopted, but did take part in developing), 165 identified a special functional-
ity, property, or effect in the product that is particularly attributable to its
nanotechnology-related aspect. Many products beyond those cross-
referenced under Class 977 would qualify under whatever criteria the FDA
adopts, but this method provides a starting point with the benefit of provid-
ing a bright line rule for manufacturers seeking to comply with FDA regu-
lations, and providing the FDA with an easy way to identify potentially
harmful products.
Of course, identifying nanotechnology-related products as "new" for
legal or safety purposes will not create the desired effect unless the product
is going to be regulated differently than it would have been regulated with-
out the "new" label. In the case of a nanosized GRAS product, for example,
classification as "new" has an immediate impact-the nanosized version of
the GRAS product will no longer be recognized as safe. But for other prod-
163. TAYLOR, supra note 22, at 8.
164. Id.
165. FDA Nanotechnology FAQ, supra note 1.
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ucts, more than the "new" label is needed. It would be a meaningless exer-
cise for the FDA to classify a nanoparticulate-containing skin-firming lo-
tion as "new" if the result is that the lotion remains classified as a cosmetic,
because that cosmetic would still not be subject to pre-market regulation.
There are two potential solutions to this problem. First, the FDA could
use its labeling power to encourage manufacturers to conduct safety re-
search on their products. For instance, the FDA can consider a cosmetic
product containing even one ingredient "whose safety [has not been] ade-
quately substantiated prior to marketing" to be technically misbranded
unless it contains a warning label. 166 The FDA should enforce this labeling
requirement for Class 977 products immediately. To do so would create a
strong incentive for cosmetic manufacturers to substantiate their products'
safety by funding new research. Even manufacturers of nanotechnology-
containing cosmetics that are already on the market can be pressured into
substantiating their products' safety. For cosmetics having a "history of
use," once an ingredient's safety is brought into question the manufacturer
must provide a warning label unless (1) there was previous substantiation
of the product's safety, (2) the new information does not demonstrate a
human health hazard, and (3) "[a]dequate studies are being conducted to
determine expeditiously the safety of the ingredient or product."' 167 This
begs the question as to what "adequate substantiation" actually means, but
if the FDA adopts a working definition of nanotechnology and creates a list
of criteria for classifying products as "new" for various purposes, manufac-
turers would have greater clarity as to what is required of them. Either way,
manufacturers would research the effects of Class 977 products on public
health and safety. Further, if these requirements alone do not suffice, the
warning labels may create enough public pressure to coerce manufacturers
into substantiating product safety. Companies have bowed to pressure in
the past when consumers have expressed concern about the lack of product
regulation. In 2005, for instance, L'Oreal and Revlon agreed to eliminate
from nail polish and other cosmetics certain chemicals suspected of causing
cancer, birth defects, and infertility after groups like the Breast Cancer
Fund pressured the companies to do So. 168
Second, the FDA should use the Class 977 cross-reference to create a
presumption that the product is likely to fall within more than one of its
regulatory categories. Such a product might, for example, meet the defini-
166. 21 C.F.R. § 740.10(a) (2007).
167. Id. § 740.10(b)(1)-(3).
168. See Laurel Naversen Geraghty, Should You Worry About the Chemicals In Your Makeup?,
N.Y. TIMES, July 7, 2005, at G3.
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tion of both a cosmetic and a drug, or the product might be an "official"
combination product that combines aspects of a drug, a biologic, or a medi-
cal device.169 In the case of "official" combination products, the FDA can
continue to use its method of identifying the product's PMOA to assign it
to the appropriate office. Upon the identification of an "unofficial" combi-
nation product (i.e. a product that combines aspects of more than one regu-
latory category but does not meet the definition provided in 21 C.F.R.
§ 3.2(e)), the FDA should strongly enforce its own requirement that the
product meet the standards set forth for both regulatory categories. 170
Since, as the FDA notes, "[a]pplications for new drugs must demonstrate
the product's safety and efficacy or the product's bioequivalence to a pre-
viously approved drug product," this would provide additional insurance
that at least some of the Class 977 products would be subject to health and
safety research.171
VI. A CALL TO ACTION
The FDA needs to act before more nanotechnology products are
placed on the market without adequate oversight. Not only does the FDA
undermine its own position as a public protector, but its failure to address
nanotechnology when other regulatory agencies are doing so undermines
those agencies' abilities to fulfill their mandates. For instance, the EPA has
published an external review draft of a white paper on nanotechnology,
provided numerous grants and funded research on nanotechnology's impact
on the environment, and held workshops and conferences on nanotechnol-
ogy. 172 The NIOSH has likewise published a "strategic plan" for dealing
with gaps in nanotechnology health and safety knowledge, and published a
paper that reviews what NIOSH currently knows about nanoparticle toxic-
ity and control. 173 This document requests input from "occupational safety
and health practitioners, researchers, product innovators and manufacturers,
169. 21 C.F.R. § 3.2(e).
170. Cosmetic, Drug, or Soap, supra note 152.
171. FDA Nanotechnology FAQ, supra note 1.
172. U.S. ENVIRONMENTAL PROTECTION AGENCY, NANOTECHNOLOGY WHITE PAPER (2007),
available at http://es.epa.gov/ncer/nano/publications/whitepaperl2022005.pdf; U.S. Environmental
Protection Agency, Nanotechnology, http://es.epa.gov/ncer/nano/factsheet/ (last visited Apr. 6, 2008).
173. NAT'L INST. FOR OCCUPATIONAL SAFETY AND HEALTH, APPROACHES TO SAFE
NANOTECHNOLOGY: AN INFORMATION EXCHANGE WITH NIOSH (2006) [hereinafter NIOSH, SAFE
NANOTECHNOLOGY], available at http://www.cdc.gov/niosh/topics/nanotech/safenano/pdfs/approaches
_tosafe_nanotechnology.28november2006_updated.pdf; Nat'l Inst. for Occupational Safety and
Health, Strategic Plan for NIOSH Nanotechnology Research, http://www.cdc.gov/niosh/topics/nanotech
/strat-plan.html (last visited Apr. 6, 2008).
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employers, workers, interest group members, and the general public."'1 74
These agencies admit that they do not have all the information that they
need, but they are nevertheless taking steps toward establishing an interim
framework for regulation while the necessary information is acquired. If
the FDA does not act, nanotechnology products released on the market may
adversely impact not only the health of consumers, but the health of the
nation's environment and the health of its workers.
Another concern is that if the FDA does not act quickly to regulate
nanotechnology products, the public will lose confidence in the products'
safety. Ensuring that the public gets accurate information about nanotech-
nology is not only important for consumers, but key for manufacturers as
well, because public perception can dictate whether a market will exist for
the products of nanotechnology. The FDA's mission is more than simply
regulating new products and protecting the public health. The FDA is also
responsible for "helping the public get the accurate, science-based informa-
tion they need to use medicines and foods to improve their health."' 175 Pub-
lic confidence in the FDA as an administrative agency has fallen over the
last few years.176 The FDA must counter this perception with regard to
nanotechnology products in particular, because "[p]erceived risks may very
well constitute the tipping point that will decide whether nanotechnology
succeeds."1 77
One has only to think back to genetically modified corn to realize the
impact that public perception has on product success. 178 In that case, the
EPA approved a strain of corn that was resistant to a particularly threaten-
ing insect, but was not harmful to other insects, humans, or animals. Four
years later, a paper in the journal Nature claimed that the genetically modi-
fied corn pollen harmed monarch butterfly larvae. 179 Immediate public
outcry followed, and the European Union banned the corn entirely. 180 Later
174. NIOSH, SAFE NANOTECHNOLOGY, supra note 173, at ix.
175. U.S. Food & Drug Admin., FDA Mission Statement, http://www.fda.gov/opacom/more
choices/mission.html (last visited Apr. 6, 2008).
176. Press Release, Harris Interactive News, The FDA's Reputation with the General Public Is
Under Assault (May 26, 2006), available at http://www.harrisinteractive.com/news/allnewsbydate.asp?
NewslD=1060. In 2004, for instance, 56% of people felt that the FDA did a "good or excellent" job in
ensuring that innovative products get to the market quickly; in 2006, the numbers were roughly re-
versed, with 70% having a negative view of the FDA's ability to do so.
177. Emmanuelle Schuler, Perception of Risks and Nanotechnology, in DISCOVERING THE
NANOSCALE, supra note 3, at 279, 283. See generally JANE MACOUBRIE, INFORMED PUBLIC
PERCEPTIONS OF NANOTECHNOLOGY AND TRUST IN GOVERNMENT (2005), available at
http://www.wilsoncenter.org/news/docs/macoubriereport.pdf.
178. Schuler, supra note 177, at 279, 280-81.
179. John E. Losey, Linda S. Rayor & Maureen E. Carter, Transgenic Pollen Harms Monarch
Larvae, 399 NATURE 214 (1999).
180. Schuler, supra note 177, at 279, 280-81.
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studies contradicted the earlier results, but neither publication of those stud-
ies nor the EPA's statement of confidence in the safety of the corn could
save it. 181
In the regulatory vacuum that exists at the FDA, there is the risk that a
single negative incident like that seen with genetically modified corn could
completely undermine public confidence in nanotechnology and derail
future efforts at new product development. 182 The now-infamous incident
with "Magic Nano" underscores the point. Magic Nano was an aerosol
glass and ceramic tile sealant marketed in Germany.183 It was recalled just
three days after being released on the market, after approximately 100 con-
sumers reported symptoms such as difficulty with breathing and chest
pains. A few weeks later, German regulatory authorities released tests
showing that Magic Nano contained no nanoparticles whatsoever. By that
point, however, nanotechnology's reputation had taken a hit. As yet, no
American product has created a similar scare. One could easily occur, and
regardless of whether that scare is justified or not, it will impact the pub-
lic's willingness to use nanotechnology products. Even though there may
be no "inherent risks or toxicities associated with nanomaterials, the pub-
lic's perception of that is not going to be realized until ... studies are pro-
moted in concert transparently with the development of novel materials."1 84
If the FDA creates a strong regulatory network and can assure the public
that nanotechnology products are being carefully monitored, nanotechnol-
ogy will be able to survive and thrive where genetically modified foods
could not.
CONCLUSION
The FDA is struggling to come to terms with nanotechnology. That
being said, it has taken some important steps towards fulfilling its obliga-
tion to protect the public health and safety. For instance, the FDA has
formed a nanotechnology interest group, where representatives from each
181. Id. at279,281.
182. See also Kenneth David, Michigan State University, Remarks at the Public Meeting on
Nanotechnology Materials in FDA Regulated Products 73-74 (Oct. 10, 2006), transcript available at
http://www.fda.gov/nanotechnology/meetings/transcript.pdf (describing how the delay in engaging the
public hurt genetically modified foods in Britain).
183. Bamaby J. Feder, Technology's Future: A Look at the Dark Side, N.Y. TIMES, May 17, 2006,
at G4.
184. Stacey Harper, Oregon State University, Remarks at the Public Meeting on Nanotechnology
Materials in FDA Regulated Products 75-76 (Oct. 10, 2006), transcript available at
http://www.fda.gov/nanotechnology/meetings/transcript.pdf.
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center meet to discuss nanotechnology-related issues. 185 These groups
"provide a level of coordination of review for the various product
types... [, identify and define] the regulatory challenges in the various
review disciplines, [then work to] propose a path forward." 186 The FDA
also held its first public meeting on nanotechnology in October of 2006,
where it heard from a diverse group such as Friends of the Earth and the
Cosmetic, Toiletry, and Fragrance Association. 187 Within its own centers,
the FDA is beginning to conduct nanotechnology research, and is collabo-
rating with the NIH and NIEHS on studies examining the toxicity and ab-
sorption of nanosized titanium dioxide and zinc oxide in sunscreens; 188 it
also participates in the National Science and Technology Council's Sub-
committee on Nanoscale Science, Engineering and Technology.189
In addition, the FDA created a Nanotechnology Task Force in 2006;
after the FDA's public meeting on nanotechnology issues, the Task Force
released a report on its findings. 190 While adhering to the FDA's stance that
"nanoscale materials present regulatory challenges similar to those posed
by products using other emerging technologies," the Task Force took a
vital and long-overdue step by recognizing that nanotechnology may create
special problems, "both because nanotechnology can be used in, or to
make, any FDA-regulated product, and because, at this scale, properties of
a material relevant to the safety and ... effectiveness of FDA-regulated
products might change repeatedly as size enters into or varies within the
nanoscale range."' 191 The Task Force noted that for many of the products
discussed above, such as GRAS products and cosmetics, "the agency's
oversight capacity is less comprehensive" and the FDA may need to take
185. Press Release, FDA Forms Internal Nanotechnology Task Force (Aug. 9, 2006), available at
http://www.fda.gov/bbs/topics/NEWS/2006/NEW01426.html; U.S. Food & Drug Admin., Nanotech-
nology, http://www.fda.gov/nanotechnology/ (last visited Apr. 6, 2008).
186. FDA Nanotechnology FAQ, supra note 1.
187. U.S. Food & Drug Admin., Draft Agenda: Public Meeting on Nanotechnology Materials in
FDA Regulated Products, http://www.fda.gov/nanotechnology/agendal010.html (last visited Apr. 6,
2008).
188. FDA Nanotechnology FAQ, supra note 1.
189. Id.
190. NANOTECHNOLOGY TASK FORCE, NANOTECHNOLOGY: A REPORT OF THE U.S. FOOD AND
DRUG ADMINISTRATION (2007), available at http://www.fda.gov/nanotechnology/taskforce/report
2007.pdf.
191. Id. at ii. The report also states that "[tihere may be a fundamental difference in the kind of
uncertainty associated with nanoscale materials compared to conventional chemicals, both with respect
to knowledge about them and the way that testing is performed," id. at 13, and expressed some concern
about the lack of predictability in biological interactions, since "particle size range or particle concen-
trations [which could cause an adverse] increase in reactivity... would depend on adaptive responses
of the affected biological system.., and, therefore, would be difficult to predict in the absence of test
data." Id. at 10.
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additional steps to ensure product safety. 192 The report, which was en-
dorsed by the Commissioner of the FDA, 193 makes a number of key rec-
ommendations, including that the FDA actively monitor research into the
hazards of various nanoscale materials, develop standards for characteriz-
ing nanoscale materials, reassess the way in which nanotechnology-related
combination products are assigned to FDA centers, and issue guidance to
product manufacturers. 194
Each of these actions should be applauded, but the fact remains that
the FDA is simply not doing enough to address the challenges that it admits
exist. 195 Other agencies, such as the USPTO, have propagated working
definitions and rules to address the unique aspects of nanotechnology-
related products and inventions. The FDA should take advantage of the
information generated by the USPTO, as well as other agencies, to help it
fulfill its role in ensuring the public health and safety. By taking a few
small steps now, the FDA can do its part to ensure that American consum-
ers reap the big rewards of tiny technology.
192. See id. at iii, 33-34.
193. Memorandum from Andrew C. von Eschenbach to the Deputy Comm'r for Policy and the
Associate Comm'r for Science (July 23, 2007), available at http://www.fda.gov/nanotechnology/
taskforce/report2007.pdf.
194. NANOTECHNOLOGY TASK FORCE, supra note 190, at 14, 18, 20, 30-34.
195. See supra note 191 and accompanying text. As the FDA put it:
Issues that [the] FDA anticipates include: The likelihood that many of the nanotechnology
products that the Agency regulates will be Combination Products (i.e., drug-device, drug-
biologic, or device-biologic products). Because [the] FDA regulates products based on their
statutory classification rather than the technology they employ, [the] FDA's regulatory con-
sideration of an application involving a nanotechnology product may not occur until well after
the initial development of that nanotechnology. Because [the] FDA has limited regulatory au-
thority over certain categories of products, the Agency may have limited authority over the
use of nanotechnology related to those products. For example, there is no premarket approval
of cosmetic products or their ingredients, with the exception of color additives.
FDA Nanotechnology FAQ, supra note I.
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